Cadrenal Therapeutics, Inc. (CVKD) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cadrenal Therapeutics, Inc. on March 31, 2026. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Ponte Vedra, Florida. The report details a material definitive agreement entered into on March 31, 2026, regarding a warrant inducement transaction.
Key Financial Metrics and Transaction Details
- Transaction Type: Warrant Inducement Agreement and issuance of new warrants.
- Expected Gross Proceeds: Approximately $2.5 million from the exercise of existing warrants.
- Shares to be Issued (Existing Warrants): 571,430 shares of Common Stock.
- Exercise Price (Existing Warrants): Reduced from $16.50 to $4.50 per share.
- New Securities Issued:
- Series B-1 Warrants: 571,430 shares (5-year term).
- Series B-2 Warrants: 571,430 shares (18-month term).
- Placement Agent Warrants: Up to 37,143 shares (6.5% of existing warrant shares).
- Exercise Price (New Warrants): $4.50 per share.
- Placement Agent Fees: 7.0% cash fee plus warrants with an exercise price of $5.625 per share.
- Use of Proceeds: Working capital purposes.
Material Changes and Transaction Mechanics
The Company entered into an agreement with a holder of existing warrants (issued November 4, 2024) to induce the exercise of those warrants at a significantly reduced price. In exchange for the holder agreeing to exercise the warrants for cash, the Company issued new unregistered warrants (Series B-1 and B-2) covering 100% of the shares underlying the exercised warrants for each series. The transaction is expected to close on April 1, 2026. The Company has agreed to a 15-day lock-up period following the closing date, during which it will not issue additional shares or file new registration statements, subject to limited exceptions.
Outlook, Risks, and Contingencies
- Registration Obligations: The Company must file a Form S-3 to register the resale of New Warrant Shares within 30 days and use commercially reasonable efforts to have it declared effective within 60 days (or 90 days if reviewed).
- Cashless Exercise Right: If the resale registration statement is not effective after 60 days, holders may elect to exercise warrants on a cashless basis.
- Ownership Limitations: Holders cannot exercise warrants if it would result in beneficial ownership exceeding 4.99% (or 9.99% upon election) of outstanding shares.
- Fundamental Transaction Rights: In the event of a Fundamental Transaction, holders have the right to require the Company to purchase the unexercised warrants for cash at their Black Scholes Value, subject to specific conditions regarding transactions not in the Company's control.
- Financial Data: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics outside of the specific transaction proceeds.
Key Facts for Investor Verification
- Verify the closing of the transaction on April 1, 2026, and the actual receipt of the $2.5 million in gross proceeds.
- Monitor the filing and effectiveness of the Resale Registration Statement (Form S-3) within the mandated 30 to 60-day window.
- Assess the dilution impact of the issuance of 1,142,860 new warrant shares (Series B-1 and B-2) plus 37,143 placement agent warrants.
- Review the Company's current cash position to determine the necessity of this capital raise for working capital.
- Confirm the identity of the "Holder" exercising the warrants to understand potential concentration of ownership.